Statera Biopharma EBIT per Share
The EBIT per Share of Statera Biopharma (STAB) as of Oct 28, 2026 is -0.85 USD. In the previous year, EBIT per Share was -0.21 USD — a change of 308.40% (lower).
Get this data via API
Financial Data API
EBIT per Share
-0.85USD
YoY
308.40%
Last updated:
The Statera Biopharma EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -0.85USD | +308.40% | |
| -0.21USD | +0.01% | |
| -0.21USD | -50.88% | |
| -0.43USD | -15.04% | |
| -0.50USD | -13.52% | |
| -0.58USD | -62.13% | |
| -1.53USD | -71.40% | |
| -5.34USD | -46.72% | |
| -10.03USD | -37.58% | |
| -16.07USD | +4.31% | |
| -15.40USD | +87.90% | |
| -8.20USD | +5.37% | |
| -7.78USD | -63.67% | |
| -21.42USD | -50.46% | |
| -43.23USD | +162.20% | |
| -16.49USD | +105.28% | |
| -8.03USD | -26.69% | |
| -10.96USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Statera Biopharma Stock analysis
Frequently Asked Questions about Statera Biopharma stock
EBIT per Share of Statera Biopharma is -0.85 USD in 2021.
EBIT per Share of Statera Biopharma changed from -0.21 USD to -0.85 USD, representing a 308.40% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Statera Biopharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Statera Biopharma
All Key Metrics — Statera Biopharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth